Pediatric brain cancer is one of the most common forms of disease diagnosed in children. Market Research Future, a firm which specializes in market reports related to the healthcare sector among others, published in its recent report on ‘Pediatric Brain Tumor Market Research Report – Global Forecast till 2023’, that the global pediatric brain tumor market is growing at the CAGR of 4.1% during the forecast period and expected to reach US$ 1659.4 million by 2023. Increasing incidences of pediatric brain tumor are being identified around the world which has contributed gradually to the growth of the market.
The main causative factor for pediatric brain tumor market is genetics. Most of the tumors are diagnosed after child birth till 12 years of age, which is usually detected after appearance of certain symptoms. Due to the appearance of additional types of mutations in terms of pediatric brain tumor, the scope of the market has widened significantly. Most of the tumors currently known in this particular cancer category can be divided into treatable and untreatable. For the treatable types of cancer there are drugs and procedures that are widely employed with their demand growing considerably. Extensive R & D for the untreatable cancer types is being carried out extensively in terms of operating procedures and drugs, with both these types of pediatric brain tumors increasing the demand and leading to the expansion of the market significantly.
Get a sample report at https://www.marketresearchfuture.com/sample_request/3690 .
Increase in the level of access to therapies, high level of medical assistance, need for specialized medicines and surgical knowledge have prompted the growth levels in the pediatric brain tumor market segment. The market for pediatric brain tumors can be restricted due to factors such as high cost of treatment, clinical trial challenges and relatively rate of diagnosis.
Latest Industry News:
July 2017 Epizyme, Inc which is a clinical-stage biopharmaceutical company creating novel epigenetic therapies, announced recently that the National Cancer Institute (NCI), part of the National Institutes of Health, has initiated its NCI-COG Pediatric MATCH study, which includes a phase 2 evaluation of tazemetostat as one of its treatment arms. The multi-institutional study will evaluate tazemetostat as a monotherapy for pediatric patients with advanced solid tumors, including CNS tumors, non-Hodgkin lymphoma or histiocytic disorders.
Dec 2017 Alcyone Lifesciences has recently announced their first pediatric patient treated with AMC for treatment of DIPG. Alcyone MEMS Cannula platform was used in a Phase 1 study for a certain type of brain tumor called diffuse intrinsic pontine glioma (DIPG). Due to the difficult anatomical location of the tumor, there is no effective treatment until now, and dsurgical resection is often not possible as it can be challenging for treating DIPG cases.
Pediatric Brain Tumor – Competitive Analysis
With the entry of new industry players in the bioidentical hormones segment, a trend of solid, volume-driven growth has been observed in the market with the addition of new and advanced products and treatment methods. Companies are aiming to capture & solidify their share of the market segment, by competing and experimenting with various advantage points. The best long-term growth opportunities for this sector can be captured by ensuring ongoing process improvements and financial flexibility to invest in the optimal strategies.
Some of the key players in this market are Abbott, AbbVie Inc, Akorn Inc, Agios Inc, Baxter, Bayer AG. Other notable players in the market are Epizyme, Inc., Novartis AG (Switzerland), Mylan N.V, and others
Browse Complete Report at https://www.marketresearchfuture.com/reports/pediatric-brain-tumor-market-3690 .
Pediatric Brain Tumor – Segments
Global pediatric brain tumor market has been segmented on the basis of types, diagnosis, treatment and end user.
On The Basis Of Types: Gliomas, Mixed Neuronal-Glial Tumors, Embryonal Tumors, Choroid Plexus Papilloma/Carcinoma, Non-Neuroepithelial Tissue Tumors, Meningeal Tumors, & Others.
Gliomas Is Further Sub-Segmented Into Astrocytoma, Malignant Gliomas, & Others.
Mixed Neuronal-Glial Tumors Are Further Sub-Segmented Into Ganglioglioma, Subependymal Giant Cell Tumor, Pleomorphic Xanthoastrocytoma, & Others.
Embryonal Tumors Are Further Sub-Segmented Into Primitive Neuroectodermal Tumor (PNET), Atypical Teratoid/Rhabdoid Tumor, & Others.
Tumors Arising From Non-Neuroepithelial Tissue Are Further Sub-Segmented Into Craniopharyngioma, Pineal Region Tumors, & Others.
On The Basis Of Diagnosis: Physical Exam, Imaging Tests, Brain or Spinal Cord Tumor Biopsy, Llmbar Puncture (Spinal Tap), Blood & Urine Tests, & Others.
Imaging Tests Are Further Sub-Segmented Into Magnetic Resonance Imaging (MRI) Scan, Computed Tomography (CT) Scan, Positron Emission Tomography (PET) Scan, Angiogram, & Others.
Magnetic Resonance Imaging (MRI) Scan Is Further Sub-Segmented Into Magnetic Resonance Angiography (MRA), Magnetic Resonance Spectroscopy (MRS), Magnetic Resonance Perfusion, Functional MRI (FMRI), & Others.
Brain Or Spinal Cord Tumor Biopsy Is Further Sub-Segmented Into Stereotactic Needle Biopsy, Craniotomy, & Other.
On The Basis Of Treatment: Surgery, Therapies, Drug Treatment, & Others.
Surgery Is Further Sub-Segmented Into Surgical Biopsy, Resection (Removal), Shunt Placement/Revision, & Others. Therapies Includes Radiation Therapy, Chemotherapy, Targeted Therapy, & Others.
Chemotherapy Includes Carboplatin, Carmustine (BCNU), Cisplatin, Cyclophosphamide, Etoposide, Lomustine (CCNU), Methotrexate, Temozolomide, Thiotepa, Vincristine, & Others.
Drug Treatment Is Further Sub-Segmented Into Corticosteroids, Anti-Seizure Drugs (Anti-Epileptics), Hormones, & Others.
On The Basis Of End User: Hospitals & Clinics, Medical Research Centers, Academic Institutes, & Others.
Get a discount at https://www.marketresearchfuture.com/check-discount/3690 .
Pediatric Brain Tumor – Regional Analysis
The global pediatric brain tumor market is segmented into North America, Europe, APAC, and Rest of the World (RoW).Considering the global scenario of the market, North America holds the largest market share owing to various factors such as increasing cases of pediatric brain tumors and related medical complications. Europe is the second largest market where the countries like Germany and UK are holding the largest market share. In 2014, about 10,000 new cases of pediatric brain tumors were observed. New cases of pediatric brain tumor are rapidly growing in Asia Pacific region. Additionally, improving healthcare sector, government initiatives to improve public health and rising healthcare spending are driving the growth for Asia Pacific pediatric brain tumor market. Due to low knowledge of disease, limited availability of medical facilities, Middle East and Africa (ME&A) is likely to have a limited growth in the market.
Company Name: Market Research Future
Contact Person: Akash Anand
Phone: +1 646 845 9312
Address:Market Research Future Office No. 528, Amanora Chambers Magarpatta Road, Hadapsar, Pune –